热门资讯> 正文
Tectontic获得FDA批准开始对先导药物TX45进行临床测试
2024-07-31 06:54
- Tectonic Therapeutics (NASDAQ:TECX) said it has received FDA clearance for its Investigational New Drug application for TX45 for the treatment of a type of pulmonary hypertension.
- The company said it intends to initiate a Phase 2 study of the drug in Q3 for the treatment of patients with Group 2 pulmonary hypertension due to heart failure with preserved ejection fraction. Topline results are anticipated in 2026, according to a statement.
- Tectonic added that topline results from a Phase 1a study of TX45 are expected to be released in September, while topline results from a Phase 1b study are anticipated in mid-2025.
- Tectonic merged with AVROBIO in June.
More on AVROBIO
- Tectonic, AVROBIO complete merger, announce $130.7M private placement
- Historical earnings data for AVROBIO
- Financial information for AVROBIO
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
